Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib

Leukemia Research

Volumn 35, Issue 9, 2011, Pages 1164-1169

  Latagliata, Roberto ^a   Breccia, Massimo ^a   Castagnetti, Fausto ^b   Stagno, Fabio ^c   Luciano, Luigiana ^d   Gozzini, Antonella ^e   Ulisciani, Stefano ^f   Cavazzini, Francesco ^g   Annunziata, Mario ^h   Sorà, Federica ⁱ   Rossi, Antonella Russo ^j   Pregno, Patrizia ^k   Montefusco, Enrico ^l   Abruzzese, Elisabetta ^m   Crisà, Elena ⁿ   Musto, Pellegrino ^o   Tiribelli, Mario ^p   Binotto, Gianni ^q   Occhini, Ubaldo ^r   Feo, Costanzo ^s   Vigneri, Paolo ^b   Santini, Valeria ^e   Fava, Carmen ^f   Rosti, Giannantonio ^b   Alimena, Giuliana ^a   more..

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Ospedale Ferrarotto   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f Ematologia Polo Universitario ASO San Luigi Gonzaga   (Italy)

^g UNIVERSITY OF FERRARA   (Italy)

^h CARDARELLI HOSPITAL   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j UNIVERSITY OF BARI   (Italy)

^k MOLINETTE HOSPITAL   (Italy)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m S EUGENIO HOSPITAL   (Italy)

ⁿ UNIVERSITY OF TURIN   (Italy)

^o REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^p UNIVERSITY OF UDINE   (Italy)

^q UNIVERSITY OF PADOVA   (Italy)

^r IRCCS POLICLINICO SAN DONATO   (Italy)

^s DH Ematologico   (Italy)

more..

Author keywords

Chronic Myeloid Leukaemia; Dasatinib; Elderly; Safety

Indexed keywords

DASATINIB; IMATINIB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASCITES; BLOOD TOXICITY; BONE PAIN; BRONCHOPNEUMONIA; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DEEP VEIN THROMBOSIS; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; FEMALE; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HEART MUSCLE ISCHEMIA; HUMAN; KERATOCONJUNCTIVITIS; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; DRUG TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PYRIMIDINES; RETROSPECTIVE STUDIES; THIAZOLES; TREATMENT OUTCOME;

EID: 80051471275     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.015     Document Type: Article

References (19)

1. Druker B.J., Guilhot F., O'Brien S.G., Gathmann I., Kantarjian H., Gattermann N., et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408-2417.
2. Branford S., Seymour J., Grigg A., Arthur C., Rudzki Z., Lynch K., et al. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 2007, 13:7080-7086.
3. Hochhaus A., Druker B., Sawyers C., Guilhot F., Schiffer C.A., Cortes J., et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2008, 111:1039-1043.
4. Branford S., Rudzki Z., Walsh S., Parkinson I., Grigg A., Szer J., et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003, 102:276-283.
5. Kujawski L., Talpaz M. Strategies for overcoming imatinib resistance in chronic myeloid leukemia. Leuk Lymph 2007, 48:2310-2322.
6. O'Hare T., Walters D.K., Stoffregen E.P., Jia T., Manley P.W., Mestan J., et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005, 65:4500-4505.
7. Tokarski J.S., Newitt J.A., Chang C.Y., Cheng J.D., Wittekind M., Kiefer S.E., et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006, 66:5790-5797.
8. Hochhaus A., Kantarjian H.M., Baccarani M., Lipton J.H., Apperley J.F., Druker B.J., et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007, 109:2303-2309.
9. Hochhaus A., Baccarani M., Deininger M., Apperley J.F., Lipton J.H., Goldberg S.L., et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia 2008, 22:1200-1206.
10. Kantarjian H.M., Pasquini R., Levy V., Jootar S., Holowiecki J., Hamerschlak N., et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized Phase 2 study (START-R). Cancer 2009, 115:4136-4147.
11. Shah N.P., Kim D.W., Kantarjian H.M., Rousselot P., Llacer P.E., Enrico A., et al. Potent, transient inhibition of BCR-ABL with dasatinib 100mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 2010, 95:232-240.
12. Cortes J., Talpaz M., O'Brien S., Giles F., Beth Rios M., Shan J., et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003, 15(98:):1105-1113.
13. Latagliata R., Breccia M., Carmosino I., Sarlo C., Montefusco E., Mancini M., et al. Older patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res 2005, 29:287-291.
14. Rosti G., Iacobucci I., Bassi S., Castagnetti F., Amabile M., Cilloni D., et al. Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party. Haematologica 2007, 92:101-105.
15. Rohrbacher M., Berger U., Hochhaus A., Metzgeroth G., Adam K., Lahaye T., et al. Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia 2009, 23:602-604.
16. Baccarani M., Saglio G., Goldman J., Hochhaus A., Simonsson B., Appelbaum F., et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood 2006, 108:1809-1818.
17. Hughes T., Deininger M., Hochhaus A., Branford S., Radich J., Kaeda J., et al. patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006, 108:28-37.
18. Branford S., Fletcher L., Cross N.C., Muller M.C., Hochhaus A., Kim D.W., et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008, 112:3330-3338.
19. Muller M.C., Erben P., Saglio G., Gottardi E., Nyvold C.G., Schenk T., et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008, 22:96-102.